Insights into the Transforming Growth Factor-β Signaling Pathway in Cutaneous Melanoma

Carole Yolande Perrot¹⁻³, Delphine Javelaud¹⁻³, Alain Mauviel¹⁻³

¹Institut Curie, Team “TGF-β and Oncogenesis”, Equipe Labellisée Ligue Contre le Cancer, ²INSERM U1021, ³CNRS UMR 3347, Orsay, France

Transforming growth factor-β (TGF-β) is a pleiotropic growth factor with broad tissue distribution that plays critical roles during embryonic development, normal tissue homeostasis, and cancer. While its cytostatic activity on normal epithelial cells initially defined TGF-β signaling as a tumor suppressor pathway, there is ample evidence indicating that TGF-β is a potent pro-tumorigenic agent, acting via autocrine and paracrine mechanisms to promote peri-tumoral angiogenesis, together with tumor cell migration, immune escape, and dissemination to metastatic sites. This review summarizes the current knowledge on the implication of TGF-β signaling in melanoma.

(introduction)

Melanoma, a neoplasm of the skin that arises from the transformation of melanocytes, is the most lethal of cutaneous malignancies¹. Many factors are now known to contribute to the formation of melanoma, including exposure to ultra-violet radiation, skin type, hair/eye color, the presence of dysplastic nevi and/or increased nevi number, and family history of melanoma². Mutations of several oncogenes, including NRAS, BRAF, CKIT and cyclin-dependent kinase (CDK) and tumor suppressors such as CDKN2A (p16Ink4A) and p53, are linked to melanoma development³⁻⁵. BRAF mutations are found in 70% of all melanomas and more than 90% of these mutations carry a single missense mutation consisting in an activating substitution of glutamate for valine at position 600 (BRAFV600E) within the kinase domain of this protein⁶⁻⁷. CDKN2A is a gene involved in familial melanoma pathogenesis and a germline mutation is found among melanoma-prone families⁸. Additionally, rare germline mutations of CDK4 are exclusively found in individuals with genetic predisposition to melanoma⁹.

Increased survival of melanoma patients has been observed over the recent decades, which may be due to earlier detection (and subsequent surgical resection) of primary melanoma lesions. Yet, therapeutic options for unresectable or metastatic melanoma remain extremely limited. Until recently, dacarbazine and interleukin-2 (IL-2) were the only two agents approved by the US Food and Drug Administration (FDA) for the treatment of metastatic melanoma. In 2011, two additional drugs were approved by the FDA: Vemurafenib (Plexxikon/ZelborafTM, Roche, Basel, Switzerland) and Ipilimumab. Vemurafenib is an oral agent that targets mutant BRAF, while Ipilimumab is a fully human monoclonal antibody against cytotoxic T-lymphocyte antigen 4 (CTLA-4) that is expressed on the surface of activated T cells. This novel immunotherapy increases cell-mediated immunity by blocking the key immune checkpoint molecule CTLA-4, thus enhances natural anti-tumor immune response. Despite early therapeutic benefit of these drugs, materialized by rapid and spectacular regression of tumors, resistance rapidly occurs, with brutal tumor relapse.

Melanoma displays multifactorial etiology and its genetic and immunological background has not yet been fully understood. This review aims to provide an overview of the current knowledge on the implication of TGF-β signaling in melanoma, with a focus on recent advances in the field.

Keywords: Melanoma, Metastasis, TGF-beta signaling, Therapeutic-targets
elucidated. In vitro studies indicate that cultured melanoma cell lines produce excessive levels of cytokines and growth factors with pleiotropic biological activities. Among them, Transforming growth factor β (TGF-β) functions as an autocrine and paracrine factor that drives many cellular processes including tumor growth, invasion, escape from immune surveillance, angiogenesis and metastasis. We herein provide in-depth analysis of the relationship between melanoma progression and TGF-β signaling.

**TGF-β SIGNALING**

The canonical TGF-β signaling cascade is well characterized. Briefly, TGF-β ligands bind to the type II transmembrane receptor serine/threonine kinases (TβRII), which in turn assembles with, phosphorylates and activates type I receptor (TβRI; ALK5). Activated TβRI phosphorylates the downstream effectors SMAD2 and SMAD3, which then associate with SMAD4 (Fig. 1). This new complex accumulates in the cell nucleus where it regulates the transcription of various target genes. SMAD7, an inhibitory SMAD, interferes with TGF-β signaling by several mechanisms: it can bind TβRI to prevent SMAD2/3 phosphorylation and activation, or recruit the protein phosphatase PP1/GADD34 or the E3 ubiquitin ligases SMURF1 and SMURF2 to the receptor complex, leading to either receptor dephosphorylation or proteasomal degradation, respectively. TGF-β pathway potentially activates other signaling pathways in a non-canonical manner, including the mitogen-activated protein kinases (MAPKs) and PI3K/AKT pathways.

**TGF-β IN MELANOCYTES AND MELANOMA**

In normal epithelial tissues, TGF-β acts as a potent cell growth inhibitor. Thus, it is generally accepted that during early stages of carcinogenesis, tumor suppressive effects of TGF-β are mainly driven by the induction of a cytostatic program. TGF-β upregulates cyclin-dependent kinase (CDK) inhibitors (p21, p15, p27Kip1 and p57Kip2), while repressing pro-proliferative factors including c-MYC and inhibitor of differentiation (ID) family members. In addition to its cytostatic effects, the TGF-β/SMAD cascade also regulates the expression of several pro-apoptotic genes, which also contribute to its tumor suppressor activities.

In advanced tumors, TGF-β signaling favors cancer cell proliferation and dissemination, peri-tumoral angiogenesis, epithelial to mesenchymal transition (EMT) of tumor cells and tumor escape from immune surveillance, thus acting as tumor promoter.

In normal melanocytes, TGF-β acts as a potent inhibitor of proliferation and differentiation. TGF-β1 represses the paired-box transcription factor PAX3, which cooperates with the homeobox transcription factor SOX10 to induce melanocyte differentiation. TGF-β may also interfere with melanocyte maturation by inhibiting of microphthalmia transcription factor (M-MITF), a master transcription factor specific of the melanocytic lineage that controls cell survival, migration and differentiation.

Cell autonomous activation of the TGF-β pathway in melanoma cell lines has been well documented. While normal melanocytes only express TGF-β1, melanoma cells express and secrete high quantities of the three TGF-β isoforms, TGF-β1, TGF-β2 and TGF-β3. TGF-β ligands are able to induce their own expression through a positive amplification loop. Furthermore, treatment of melanoma cell lines with exogenous TGF-β1 induces the secretion of active TGF-β1 and TGF-β2. Consistently, plasma levels of TGF-β are found elevated in melanoma patients, in parallel with metastatic progression. Also,
TGF-β2 expression was found to correlate with tumor thickness and invasiveness\(^2\).

Genome-wide expression analysis of nearly one hundred human melanoma cell lines identified two groups with very distinct gene expression profiles associated with distinct behaviors in vitro: the first group is characterized by high expression of neural crest and melanocytic differentiation markers and exhibits a proliferative, poorly invasive phenotype, while the other group is characterized by the expression of a number of genes whose concomitant expression is reminiscent of a TGF-β signature, and associated with a highly invasive phenotype and low proliferation rate\(^2\).

Several studies have described functional SMAD signaling in melanoma. Basal phosphorylation of SMAD3 is detectable in vitro in melanoma cells, demonstrating a constitutive activation of the TGF-β receptors. Furthermore, TGF-β blockade by means of either a neutralizing pan-TGF-β antibody\(^1\), SMAD7 overexpression\(^2\), or treatment of cells with a TβRI small molecule inhibitor\(^2\), inhibited basal SMAD3/SMAD4-dependent transcriptional activity in melanoma cells. Also, exogenous TGF-β was shown to induce further SMAD3/SMAD4-dependent transcription, demonstrating the functionality of the entire TGF-β signaling cascade. In human melanocytic lesions, high levels of nuclear phosphorylated SMAD2 are found in benign melanocytic nevi, melanomas in situ, and primary invasive melanomas, suggesting that tumor cell autonomous hyperactivation of the TGF-β/SMAD pathway can be causally related to melanoma progression in the skin, and may participate to the critical switch from radial to vertical growth during melanoma progression\(^18\). Interestingly, it has also been shown that phosphorylation of SMAD2 in melanoma cells is associated with SMAD2 phosphorylation in neighboring keratinocytes, indicating that melanoma-derived TGF-β affects the microenvironment and adjacent cells in a paracrine fashion\(^19\).

Intron 6 of the TRPM1 gene (which encodes Melastatin, a calcium permeable cation channel that may play a role in melanin synthesis) hosts the gene for miR-211, whose expression is restricted to the melanocyte lineage\(^26\). miR-211 and melastatin share the same promoter and are expressed coordinately in melanocytes and melanomas. TRPM1 is coordinately expressed with miR-211 in melanocytes and melanomas. It is robustly expressed in benign and dysplastic nevi and in melanomas in situ, but its expression is heterogeneous in invasive melanomas and is downregulated in melanoma metastases\(^27\). Interestingly, it has been shown that reducing miR-211 levels is sufficient to convert a non-invasive melanoma to an invasive melanoma, and that TβRII is one of the direct targets of miR-211\(^29\). Yet, TGF-β has been implicated in the metastatic spread of melanoma\(^17\), suggesting that increased TGF-β signaling through TβRII expression might enhance melanoma invasion and motility when miR-211 levels are low.

**MELANOMA RESPONSIVENESS TO TGF-β**

**Melanoma resistance to TGF-β-mediated growth suppression**

While normal melanocytes are growth-inhibited by TGF-β, melanoma cells exhibit a variable degree of resistance to its antiproliferative activity. The mechanisms underlying evasion from a cytostatic response to TGF-β in these cells remain somewhat elusive. Alterations in the components of the TGF-β signaling in melanoma, including loss of expression or mutation of TβRII and SMADs, are very rare\(^12\) and therefore do not explain the mechanisms of resistance of melanoma cells to TGF-β-mediated growth arrest and apoptosis.

Various mechanisms have been suggested to explain a possible attenuation or inhibition of the TGF-β signaling cascade in melanoma cells. For example, the type III TGF-β receptor CD105 (also called endoglin) was reported to bind TGF-β1 in melanoma cells and to contribute to the regulation of the anti-proliferative effects of TGF-β30.\(^31\) In melanoma cells deficient in filamin, a cytoskeletal actin-binding protein, TGF-β/SMAD signaling is defective, suggesting that filamin, which was identified as a SMAD-interacting protein, may serve as an anchor protein that allows localization of SMAD proteins near cell surface receptors, thus facilitating their phosphorylation and subsequent activation\(^12\). More recently, distal-less homeobox (DLX2), identified as a novel TGF-β-inducible transcription factor in B16 melanoma cells, was shown to exert protective function against the growth suppressive effects of TGF-β\(^32\). Also, forced expression of H11/HSPB8, an atypical heat shock protein with kinase activity that inhibits the growth of melanoma cells through activation of TGF-β activated kinase 1 (TAK1)-dependent death pathways, is silenced through aberrant promoter methylation in melanoma cells, thus contributing to resistance to TGF-β-mediated cytostasis\(^34\).

High levels of the oncoproteins SKI and SNON are detected in melanoma\(^35,36\). These proteins have been described as potent inhibitors of TGF-β signaling, acting both in the cell nucleus where they recruit transcriptional co-repressors to active SMAD complexes, and in the cytoplasm where they sequester SMAD proteins\(^11\). While it may be easily interpreted that such high expression of TGF-β pathway inhibitors is an obvious mechanism for
melanoma cells to escape the growth inhibitory activity of TGF-\(\beta\), reports from various laboratories indicate a complex regulatory network. In some melanoma cell lines, SKI or SNON knockdown inhibit cell and xenograft tumor growth\(^{36-38}\). Melanoma inhibitory activity (MIA), a protein expressed in melanoma but not in melanocytes\(^{39}\), has been shown to upregulate SKI and SNO expression via the MAPK/ERK cascade. This, in turn, was suggested to disrupt TGF-\(\beta\) signaling in melanoma cells\(^{40}\). It needs to be emphasized, however, that TGF-\(\beta\) signaling is functional in melanoma and that autocrine activation of the pathway in melanoma cell has been well documented\(^{2,17,18,41}\), underlying the complexity of TGF-\(\beta\) signaling in melanoma progression. Regarding SKI and SNON, TGF-\(\beta\) is a potent and rapid inducer of SKI and SNON degradation by the proteasome in a variety of cancer cell lines, including melanoma\(^{35,42}\). In the latter study, active and efficient TGF-\(\beta\) signaling and responsiveness was verified in melanoma cell lines, associated with rapid degradation of SKI and SNON proteins, within minutes after TGF-\(\beta\) stimulation. This event takes place not only in melanoma cells but also in various breast carcinoma cell lines\(^{42}\). Also, SKI knockdown prior to exposure to TGF-\(\beta\) did not significantly affect the extent of TGF-\(\beta\) responsiveness. Together, the latter studies indicate that TGF-\(\beta\) efficiently counteracts the ability of SKI and SNON to inhibit metastasis by inducing their degradation by the proteasome.

A number of other possible mechanisms of resistance to TGF-\(\beta\) may exist in melanoma, yet their functional relevance in disease is still ambiguous given the efficacy of TGF-\(\beta\) inhibitors to antagonize experimental melanoma progression\(^{24}\). For example, phosphorylation of the SMAD2 and SMAD3 linker regions was found to be high in both melanoma cell lines and melanoma samples\(^{43}\). Such event has previously been identified as important in the control of SMAD2/3 activity, leading to downregulation of TGF-\(\beta\)-responsive genes such as p21, p15 and c-MYC, and subsequent escape from TGF-\(\beta\)-induced cell growth arrest\(^{19}\). Yet, activation of other TGF-\(\beta\) target genes, such as PAI1, was not modified, suggesting additional, currently unknown, levels of activity control. The mechanisms responsible for SMAD2/3 linker domain phosphorylation may include MAPks (p38, JNK and ERK\(^{44-46}\)), as well as GSK3 \(^{\beta}\)\(^{47}\) and CDKs\(^{48,49}\). This is compatible with the fact that melanomas are characterized by a high incidence of activating mutations of the BRAF and NRAS oncogenes, which lead to constitutive activation of MEK/ERK signaling, and thus could participate in SMAD2/3 linker phosphorylation. Also, stable overexpression of NRAS in melanoma cells was found to interfere with TGF-\(\beta\)-induced growth inhibition via alteration of Rb protein phosphorylation\(^{50}\).

ID proteins have been shown to enhance cell cycle progression as they interfere with bHLH, ETS and PAX transcription factors (that negatively regulate CDK inhibitors such as p15\(^{51,52}\)) and bind tumor suppressor proteins like Rb\(^{53}\). Interestingly, ID2 overexpression was shown to protect melanoma cells from TGF-\(\beta\) suppression of proliferation. ID2 is differently expressed in melanoma cells according to their proliferative vs. invasive phenotype. ID2 may be downregulated by TGF-\(\beta\) in proliferative cells that respond to its growth inhibitory effect, while TGF-\(\beta\) cannot repress ID2 expression in invasive cells\(^{52}\). PAX3, which is repressed by TGF-\(\beta\) in primary melanocytes, also participates to melanoma cell survival\(^{53}\). In murine B16 melanoma cells, PAX3 overexpression was found to desensitize cells to TGF-\(\beta\)-induced growth inhibition\(^{15}\), thus representing another potential mechanism of resistance to TGF-\(\beta\) anti-proliferative effects.

**Autocrine TGF-\(\beta\) signaling promotes melanoma progression and metastasis**

Melanoma cells secrete high levels of TGF-\(\beta\) that acts on tumor cells and their microenvironment by both autocrine and paracrine mechanisms, to initiate or amplify various processes, either cell-autonomous or non cell-autonomous, that contribute to tumor progression (Fig. 2). In epithelial tumor cells, TGF-\(\beta\) pathway promotes an EMT, a critical multistep process that converts epithelial cells into motile and invasive mesenchymal-like cells. This mechanism is believed to allow cancer cells to escape from the primary tumor and to become metastatic\(^{54}\). During the transition from radial growth phase to vertical growth phase, melanoma cells undergo a process that may be considered a pseudo-EMT whereby melanoma cells acquire a fibroblastoid morphology\(^{55}\), via mechanisms that recapitulate many of the molecular characteristics of EMT\(^{56}\). In this context, TGF-\(\beta\) has been shown to promote melanoma cell pseudo-EMT through up-regulation of matrix metalloproteinase MMP9, \(\beta\) 1 and \(\beta\) 3 integrin and down-regulation of the epithelial marker E-cadherin.

The role of autocrine TGF-\(\beta\)/SMAD signaling in controlling the invasiveness and metastatic potential of melanoma cells has been described in several studies from our laboratory. In melanoma cells, we showed that overexpression of SMAD7, an inhibitory SMAD that interferes with TGF-\(\beta\) receptor function, decreases their capacity to form colonies in an anchorage-independent manner, reduces MMP2 and MMP9 secretion and Matrigel-invading capacity, and delays xenografted tumor growth in immuno-compromized mice\(^{57}\). Moreover, melanoma cells over-
Fig. 2. Autocrine and paracrine effects of transforming growth factor (TGF)-β1 on melanoma cells and tumor microenvironment. Melanoma cells express and secrete high levels of TGF-β that are self-perpetuating, notably through enhanced protease activation of latent TGF-β and recruitment of TGF-β-secreting cells such as stromal fibroblasts. TGF-β, which exerts cytostatic effects on early stage tumor cells, switches to tumor promoter in advanced melanoma where it promotes invasion, mesenchymal transition and dissemination of tumor cells. TGF-β secretion by melanoma cells also affects the tumor microenvironment. TGF-β stimulates stromal fibroblasts and endothelial cells to promote tumor growth, invasion and angiogenesis, and inhibits the proliferation and activation of key immune cells, thus allowing melanoma cells to evade from immunosuppressive actions. ECM: extracellular matrix, EndMT: endothelial to mesenchymal transition, NK: natural killer.

expressing SMAD7 were less prone than their wild-type counterparts to form experimental bone metastases following intraventricular inoculation in mice, highlighting the role of TGF-β signaling in metastatic progression. Mechanistically, SMAD7 was found to induce β-catenin degradation and promote homotypic interactions with N-cadherin between melanoma cells, and to stabilize their association with neighboring dermal fibroblasts, an additional mechanism that likely attenuates invasion. Another approach consisted in using the small molecule TβRI inhibitor SD-208 to interfere with TGF-β signaling. This pharmacologic inhibitor efficiently blocked TGF-β-induced SMAD3 phosphorylation and SMAD3/4-specific transcription, as well as Matrigel invasion by melanoma cells. Furthermore, SD-208 inhibited the expression of the TGF-β target genes parathyroid hormone-related peptide (PTHrP), IL-11, connective tissue growth factor (CTGF), and RUNX2, all involved in the development of osteolytic bone metastases. Systemic administration of SD-208 to nude mice prior to melanoma cell inoculation dramatically inhibited the establishment of osteolytic bone metastases. Also, SD-208 treatment significantly reduced the growth of established osteolytic lesions in the same mouse model of bone metastases. Most recently, we found that halofuginone, an alkaloid that interferes with TGF-β signaling through the induction of SMAD7 and repression of TβRII expression, inhibits melanoma experimental metastasis to bone and brain.

Taken together, these results demonstrate that therapeutic targeting of TGF-β may prevent the development of melanoma bone metastases and decrease the progression of established osteolytic lesions.

We also demonstrated that GLI2, a transcription factor involved in the hedgehog (HH) signaling cascade, is a direct transcriptional target of TGF-β/SMAD signaling in various cell lines, including melanoma. Accordingly with numerous studies that have established the pro-oncogenic role of GLI2 in various malignancies, GLI2 is highly expressed in aggressive melanoma cells where it regulates their invasive capacity by upregulating MMP2 and MMP9 expression. In melanoma cells, GLI2 expression is driven, at least in part, by TGF-β, and is associated with a loss of E-cadherin expression. In addition, GLI2 is a potent inducer of WNT5A and PTHrP expression, two proteins involved in the metastatic process. TGF-β also induces the expression of integrins, proteases such as cathepsin B and matrix remodeling proteins like SPARC that may be involved in the acquisition of mesenchymal traits that favor metastatic dissemination. TGF-β contribution to cathepsin B-mediated melanoma invasiveness is highly Secreted Protein Acidic and Rich in Cystein-dependent. SPARC also cooperates with interferon (IFN)-γ to repress the expression of a disintegrin and metalloproteinase (ADAM)58. Yet, ADAM15 may have tumor-suppressive functions in melanoma as it was shown to reduce the formation of lung metastases in mice and to reduce migration and invasive capacity of melanoma cells in vitro. In another study, genome-wide microarray analyses of invasive human melanomas and benign nevi revealed up-regulation of cathepsins B and L, MMP-1 and MMP-9, and urokinase- and tissue-type plasminogen activators. The mRNA levels of cathepsins B/L and plasminogen activators, but not MMPs, correlated with metastasis. Primary melanomas and benign nevi revealed that cathepsin B is predo-
ominantly expressed by melanoma cells while cathepsin L is preferentially expressed by tumor-associated fibroblasts surrounding the invading melanoma cells. Cathepsin B was shown to be important for both the production and secretion of TGF-β signaling, which in turn activates fibroblasts and subsequent invasive capacity of melanoma cells70.

In spindle tumor cells including melanoma cells, TGF-β was shown to induce the expression of fascin, an actin-bundling protein critical for metastasis. By stabilizing the actin cytoskeleton within invadopodia and filopodia, fascin coordinates the invasion and metastasis promoted by TGF-β 71.

TGF-β-induced protein (TGF-βI) is a TGF-β inducible, secreted extracellular matrix (ECM) protein shown to impair the adhesive contacts of melanoma cells with the ECM molecules fibronectin, type I collagen and laminin. TGF-βI was found to localize with the fibrillar fibronectin/tenascin-C/periostin structures that characteristically surround the invasive fronts of melanomas72.

Several cytoplasmic proteins have been identified that interact with the TGF-β receptors. Aberrant expression and/or regulation of these receptor interactors could interfere with TGF-β signaling and promote tumor development. In Xenopus, the pseudoreceptor BAMBI (bone morphogenetic protein and activin membrane-bound inhibitor) is a naturally occurring truncated type I receptor that lacks a kinase domain. It can interact with TGF-β in the presence of TβRII, binding TβRI and TβRII and disrupting ligand-induced receptor heterodimerization73. Interestingly, NMA, a mammalian orthologue of BAMBI, was identified by differential display analysis as decreased in highly metastatic melanoma74, suggesting that derepression of TGF-β signaling following a decrease of NMA expression could account for the increased metastatic potential of these cells.

Paracrine effects of TGF-β on the tumor microenvironment

Paracrine secretion of TGF-β may modulate the tumor microenvironment for the benefit of melanoma growth, invasion and metastasis, especially through its capability to activate stromal fibroblasts, its immune-suppressive effects and pro-angiogenic properties.

TGF-β-activated stromal fibroblasts can stimulate ECM protein production, including collagen, fibronectin, tenascin and α2-integrin, thus providing a scaffold that promotes melanoma cell survival, migration and metastatic progression75. Interestingly, autocrine as well as paracrine TGF-β may also promote endothelial-to-mesenchymal transition (EndMT), a process whereby endothelial cells acquire mesenchymal features and contribute to the accumulation of fibroblasts in the tumor microenvironment that facilitates tumor progression in a B16F10 melanoma model76.

During melanoma progression, tumors acquire a rich vascular network due, at least in part, to paracrine secretion of TGF-β that allows the recruitment and proliferation of endothelial cells for the development of new blood vessels. In melanoma cells, TGF-β-induced angiogenesis involves up-regulation of several pro-angiogenic factors, including IL-8 and vascular endothelial growth factor (VEGF)77.

Periostin is a TGF-β-induced ECM protein involved in cell invasion, metastasis and angiogenesis. In a murine model of human melanoma, the use of an antibody directed against a periostin epitope that corresponds to a binding site for integrins significantly reduced tumor growth and angiogenesis78.

Moreover, treatment of a B16 melanoma model with a chimeric protein derived from the fusion of IL-2 and the soluble extracellular domain of TβRII resulted in reduced angiogenesis and tumor growth79.

TGF-β negatively regulates the activity of immune cells and plays an important role in the control of T-cell functions and proliferation. For example, TGF-β blocks the production of IL-2 (a lymphokine that activates T cells, natural killer (NK) cells and other immune cells) and cell cycle regulators in T cells. TGF-β also controls the expression of effector molecules produced by cytotoxic T lymphocytes, and is an important differentiation factor for regulatory T lymphocytes (Treg), which are present in high quantities in tumors including melanoma and contribute to TGF-β-mediated immunosuppression11.

Melanoma cells, but not normal melanocytes, express monocyte chemoattractant protein-1 (MCP-1), a potent chemokine that recruits macrophages90 that in turn infiltrate melanomas and produce factors that help tumor invasion, angiogenesis and immunosuppression81. IL-10 expression has been shown in vivo in many melanoma cell lines82, and in vivo, in primary and in metastatic melanoma lesions83. Also, elevated levels of IL-10 have been observed in patients with advanced melanoma and correlate with tumor progression84. TGF-β was shown to increase the expression of MCP-1 and IL-10 in melanoma cells, an effect mediated by the crosstalk between the SMAD, PI3K/AKT and BRAF/MAPK signaling pathways85.

TGF-β AND MELANOMA THERAPY

Several TGF-β inhibitors, including small-molecule inhibitors targeting type I and II TGF-β receptor activity, mo-
noclonal antibodies neutralizing TGF-β ligands, antisense oligonucleotides blocking TGF-β ligand production and combined therapies utilizing antisense oligonucleotides together with immune-stimulating vaccines, have been developed for cancer therapy and have demonstrated efficacy in preclinical studies\textsuperscript{11}. At this stage, none of these compounds has been approved for clinical use.

In the case of melanoma treatment, several anti-TGF-β therapies have been studied such as the TGF-β 2-targeting antisense molecule AP12009 (also called Trabedersen) that has been assessed in phase I/II clinical trial in patients with advanced pancreatic or colorectal cancer and malignant melanoma. AP12009 is safe and well tolerated, and enrolled melanoma patients had somewhat improved median overall survival\textsuperscript{80}. Because TGF-β is abundantly secreted by tumor cells or by their microenvironment during disease progression, monoclonal TGF-β neutralizing antibodies and soluble TβRII or TβRIII represent a valuable therapeutic option to trap TGF-β ligands. In preclinical studies, these molecules have shown encouraging results, especially for breast cancer treatment\textsuperscript{87}. GC1008 (fresolimumab), an anti-TGF-β monoclonal neutralizing antibody, is under evaluation in a clinical phase I/II study in patients with advanced melanoma. Also, patients with advanced melanoma achieved stable disease or partial responses even if drug-related side effects were reported such as skin rash/lesions including eruptive non-malignant keratoacanthomas and squamous cell carcinomas\textsuperscript{88}. Small molecule inhibitors that target TGF-β receptor kinases are also studied for cancer treatment. A major drawback of these pharmacologic compounds is their high cardio-toxicity in humans, which has taken most of them out of clinical trials\textsuperscript{89}.

As TGF-β exerts a key role in tumor immune evasion, a novel therapeutic approach was developed, consisting in an autologous tumor cell vaccine (FANG\textsuperscript{TM}, Gradalis Inc., Carrolton, TX, USA) that incorporates a plasmid encoding both granulocyte-macrophage colony-stimulating factor (GM-CSF) and a bifunctional short hairpin RNAi (bshRNAi) directed against the proprotein convertase furin responsible for TGF-β activation. This strategy aims at downregulating endogenous immunosuppressive TGF-β 1 and 2. In a phase I trial in patients with advanced tumors, FANG\textsuperscript{TM} vaccine did not cause severe adverse events, and elicited an immune response correlated with prolonged survival\textsuperscript{90,91}. It is currently tested in phase II trials for the treatment of colon and ovarian cancer, as well as advanced melanoma.

Despite FDA approval of IL-2 for melanoma treatment several years ago, only 5–6% of patients with metastatic melanoma achieve durable complete remissions when treated with high doses of this lymphokine that induces or expands activation of melanoma-specific T-cell responses. Interestingly, IL-2 treatment combined with nanolipogel delivery of a TGF-β inhibitor was found to significant delay melanoma growth and increase survival in tumor-bearing mice, along with an increase in NK and tumor infiltrating lymphocytes (TIL) activity\textsuperscript{92}.

**CONCLUSION**

The current literature has brought ample and clear evidence for a pathogenic role of TGF-β signaling in melanoma progression to metastasis. TGF-β not only acts on melanoma cells, but also on their microenvironment including stromal fibroblasts, immune and endothelial cells. Crosstalks between these different cell types are crucial for melanoma establishment, progression and dissemination. The TGF-β signaling cascade has thus attracted much attention as a potential therapeutic target. Several TGF-β-targeting agents (combined or not with other drugs) are currently under evaluation in clinical trials for melanoma treatment and have shown promising results in enrolled patients\textsuperscript{86,88,92}. However, it is fundamental to consider the other signal transduction cascades that are known to play a role in melanoma progression, as TGF-β signaling was shown to crosstalk with some of them in epithelial cancers, including the MEK/ERK pathway.

It would be interesting to test the effects of TGF-β inhibitors combined with the new therapeutic drugs specifically targeting mutant BRAF or MEK. Finally, it is essential to take into account the influence of TGF-β on the tumor microenvironment during melanoma progression. Novel strategies that combine anti-TGF-β therapy and specific targeting of proteins involved in tumor cell-microenvironment interactions might also be worth considering.

**REFERENCES**

1. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006;20:2149-2182.
2. Jilaveanu LB, Aziz SA, Kluger HM. Chemotherapy and biologic therapies for melanoma: do they work? Clin Dermatol 2009;27:614-625.
3. Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev 2012;26:1131-1155.
4. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 2012;12:349-361.
5. Dutton-Regester K, Hayward NK. Reviewing the somatic genetics of melanoma: from current to future analytical approaches. Pigment Cell Melanoma Res 2012;25:144-154.

6. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.

7. Meyle KD, Guldborg P. Genetic risk factors for melanoma. Hum Genet 2009;126:499-510.

8. Lang JM, Shennan M, Njauw JC, Luo S, Bishop JN, Harland M, et al. A flexible multiplex bead-based assay for detecting germline CDKN2A and CDK4 variants in melanoma-prone kindreds. J Invest Dermatol 2011;131:480-486.

9. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996;12:97-99.

10. Lázár-Molnár E, Hegyesi H, Tóth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000;12:547-554.

11. Perrot CY, Javelaud D, Mauviel A. Overlapping activities of TGF-β and Hedgehog signaling in cancer: therapeutic targets for cancer treatment. Pharmacol Ther 2013;137:183-199.

12. Javelaud D, Alexaki VI, Mauviel A. Transforming growth factor-beta in cutaneous melanoma. Pigment Cell Melanoma Res 2008;21:123-132.

13. Pardal K, Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 2007;1775:21-62.

14. Rodeck U, Bossler A, Graeven U, Fox FE, Nowell PC, Knabbe C, et al. Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res 1994;54:575-581.

15. Yang G, Li Y, Nishimura EK, Xin H, Zhou A, Guo Y, et al. Inhibition of PAX3 by TGF-beta modulates melanocyte viability. Mol Cell 2008;32:554-563.

16. Kim DS, Park SH, Park KC. Transforming growth factor-beta1 decreases melelin synthesis via delayed extracellular signal-regulated kinase activation. Int J Biochem Cell Biol 2004;36:1482-1491.

17. Rodeck U, Nishiyama T, Mauviel A. Independent regulation of growth and SMAD-mediated transcription by transforming growth factor beta in human melanoma cells. Cancer Res 1999;59:547-550.

18. Lo RS, Witte ON. Transforming growth factor-beta activation promotes genetic context-dependent invasion of immortalized melanocytes. Cancer Res 2008;68:4248-4257.

19. Lasfar A, Cohen-Solal KA. Resistance to transforming growth factor β -mediated tumor suppression in melanoma: are multiple mechanisms in place? Carcinogenesis 2010;31:1710-1717.

20. Krasagakis K, Thilikos D, Farthmann B, Eberle J, Mansmann U, Orfanos CE. Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer 1998;77:1492-1494.

21. Reed JA, McNutt NS, Prieto VG, Albino AP. Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am J Pathol 1994;145:97-104.

22. Hoek KS, Schlegel NC, Brafford P, Sucker A, Uglel S, Kumar R, et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 2006;19:290-302.

23. Javelaud D, Mohammad KS, McKenna CR, Fournier P, Luciani F, Niewolna M, et al. Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res 2007;67:2317-2324.

24. Mohammad KS, Javelaud D, Fournier PG, Niewolna M, McKenna CR, Peng XH, et al. TGF-beta-R1 kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res 2011;71:175-184.

25. Mnich CD, Hoek KS, Oberholzer PA, Seifert B, Hafner J, Dummer R, et al. Reduced pSmad2 immunodetection correlates with increased primary melanoma thickness. Melanoma Res 2007;17:131-136.

26. Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 2007;67:2456-2468.

27. Duncan LM, Deeds J, Cronin FE, Donovan M, Sober AJ, Kauffman M, et al. Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol 2001;19:568-576.

28. Duncan LM, Deeds J, Hunter J, Shao J, Holmgren LM, Woolf EA, et al. Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res 1998;58:1515-1520.

29. Levy C, Khaled M, Illopolous D, Janas MM, Schubert S, Pinner S, et al. Intrinsic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell 2010;40:841-849.

30. Altomonte M, Montagner R, Fonsatti E, Coluzzi F, Cattarossi I, Brasoveanu L, et al. Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma. Br J Cancer 1996;74:1586-1591.

31. Pardal E, van der Schaft DW, Wiercinska E, Gorter A, van Kempen L, Alexaki VI, et al. Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma. Br J Cancer 1996;74:1586-1591.

32. Sasaki A, Masuda Y, Ohta Y, Ikeda K, Watanabe K. Filamin A associates with Smads and regulates transforming growth factor-beta signaling. J Biol Chem 2001;276:17871-17877.

33. Yilmaz M, Maass D, Tiwari N, Waldmeier L, Schmidt P, et al. Mutations of the BRAF gene in human cancer cell lines. Cancer Res 2007;67:2456-2468.

34. Smith CC, Lee KS, Li B, Laing JM, Hersl J, Shvartsbeyn M, et al. Reduced pSmad2 immunodetection correlates with increased primary melanoma thickness. Melanoma Res 2007;17:131-136.

35. Eiermann W, Weihe C, Luger T, Orfanos CE. Elevated plasma levels of transforming growth factor (TGF)-beta in malignant melanoma. Cytokine 2000;12:547-554.

36. Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 2007;67:2456-2468.

37. Duncan LM, Deeds J, Cronin FE, Donovan M, Sober AJ, Kauffman M, et al. Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol 2001;19:568-576.

38. Duncan LM, Deeds J, Hunter J, Shao J, Holmgren LM, Woolf EA, et al. Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res 1998;58:1515-1520.

39. Levy C, Khaled M, Illopolous D, Janas MM, Schubert S, Pinner S, et al. Intrinsic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell 2010;40:841-849.

40. Altomonte M, Montagner R, Fonsatti E, Coluzzi F, Cattarossi I, Brasoveanu L, et al. Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma. Br J Cancer 1996;74:1586-1591.

41. Pardal E, van der Schaft DW, Wiercinska E, Gorter A, Hogendoorn PC, Griffioen AW, et al. Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma. Oncogene 2011;30:334-345.

42. Sasaki A, Masuda Y, Ohta Y, Ikeda K, Watanabe K. Filamin A associates with Smads and regulates transforming growth factor-beta signaling. J Biol Chem 2001;276:17871-17877.

43. Yilmaz M, Maass D, Tiwari N, Waldmeier L, Schmidt P, Lehembre F, et al. Transcription factor Dlx2 protects from melanoma bone metastases. Cancer Res 2011;71:175-184.
noma cells associated with high c-SKI/SnoN expression. Mol Cancer 2011;10:2.  
36. Reed JA, Bales E, Xu W, Okan NA, Bandyopadhyay D, Medrano EE. Cytoplasmic localization of the oncogenic protein Ski in human cutaneous melanomas in vivo: functional implications for transforming growth factor beta signaling. Cancer Res 2001;61:8074-8078.  
37. Chen D, Lin Q, Box N, Roop D, Ishii S, Matsuizaki K, et al. SKI knockdown inhibits human melanoma tumor growth in vivo. Pigment Cell Melanoma Res 2009;22:761-772.  
38. Poser I, Rothhammer T, Dooley S, Weiskirchen R, Bosserhoff AK. Characterization of Sno expression in malignant melanoma. Int J Oncol 2005;26:1411-1417.  
39. Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zimigil H, Hein R, et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997;57:3149-3153.  
40. Rothhammer T, Bosserhoff AK. Influence of melanoma inhibitory activity on transforming growth factor-beta signaling in malignant melanoma. Melanoma Res 2006;16:309-316.  
41. Javelaud D, Alexaki VI, Dennler S, Mohammad KS, Guise TA, Mauviel A. The TGF-β/SMAD/GLI2 axis in tumor progression and metastasis. Cancer Res 2011;71:5606-5610.  
42. Le Scolan E, Zhu Q, Wang L, Bandyopadhyay A, Javelaud D, Mauviel A, et al. Transforming growth factor-beta suppresses the ability of Ski to inhibit tumor metastasis by inducing its degradation. Cancer Res 2008;68:3277-3285.  
43. Cohen-Solal KA, Merrigan KT, Chan JL, Goydos JS, Chen W, Foran DJ, et al. Constitutive Smad linker phosphorylation in melanoma: a mechanism of resistance to transforming growth factor-β-mediated growth inhibition. Pigment Cell Melanoma Res 2011;24:512-524.  
44. Kamaraju AK, Roberts AB. Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-beta-mediated Smad-dependent growth inhibition of human breast carcinomas in vivo. J Biol Chem 2005;280:1024-1036.  
45. Mori S, Matsuizaki K, Yoshida K, Furukawa F, Tahashi Y, Yamagata H, et al. TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene 2004;23:7416-7429.  
46. Matsuura I, Wang G, He D, Liu F. Identification and characterization of ERK MAP kinase phosphorylation sites in Smad3. Biochemistry 2005;44:12546-12553.  
47. Millet C, Yamashita M, Heller M, Yu LR, Veenstra TD, Zhang YE. A negative feedback control of transforming growth factor-beta signaling by glycogen synthase kinase 3-mediated Smad3 linker phosphorylation at Ser-204. J Biol Chem 2009;284:19808-19816.  
48. Alarcón C, Zaramytidou AI, Xi Q, Gao S, Yu J, Fujisawa S, et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell 2009;139:757-769.  
49. Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 2004;430:226-231.  
50. Shellman YG, Chapman JT, Fujita M, Norris DA, Maxwell IH. Expression of activated N-ras in a primary melanoma cell line counteracts growth inhibition by transforming growth factor-beta. J Invest Dermatol 2000;114:1200-1204.  
51. Norton JD. ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci 2000;113:3897-3905.  
52. Schlegel NC, Eichhoff OM, Hemmi S, Werner S, Dummer R, Hoek KS. Id2 suppression of p15 counters TGF-beta-mediated growth inhibition of melanoma cells. Pigment Cell Melanoma Res 2009;22:445-453.  
53. Scholl FA, Kamarahev S, Murmann OV, Geertes R, Dummer R, Schäfer BW. PAX3 is expressed in human melanomas and contributes to tumor cell survival. Cancer Res 2001;61:823-826.  
54. Heldin CH, Vanlandewijck M, Mostakas S. Regulation of EMT by TGF β in cancer. FEBS Lett 2012;586:1959-1970.  
55. Janji B, Melchiore C, Gouon V, Vallart L, Kieffer N. Autocrine TGF-beta-regulated expression of adhesion receptors and integrin-linked kinase in HT-144 melanoma cells correlates with their metastatic phenotype. Int J Cancer 1999;83:255-262.  
56. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013;13:97-110.  
57. Javelaud D, Delmas V, Möller M, Sextius P, André J, Menashi S, et al. Stable overexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo. Oncogene 2005;24:7624-7629.  
58. DiVito KA, Trabosh VA, Chen YS, Chen Y, Albanese C, Javelaud D, et al. Smad7 restricts melanoma invasion by restoring N-cadherin expression and establishing heterotypic cell-cell interactions in vivo. Pigment Cell Melanoma Res 2010;23:795-808.  
59. Xavier S, Piek E, Fujii M, Javelaud D, Mauvel A, Flanders KC, et al. Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone. J Biol Chem 2004;279:15167-15176.  
60. Juárez P, Mohammad KS, Yin JJ, Fournier PG, McKenna RC, Davis HW, et al. Halofuginone inhibits the establishment and progression of melanoma bone metastases. Cancer Res 2012;72:6247-6256.  
61. Dennler S, André J, Alexaki I, Li A, Magnaldo T, ten Dijke P, et al. Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. Cancer Res 2007;67:6981-6986.  
62. Dennler S, André J, Verrecchia F, Mauvel A. Cloning of the human GLI2 Promoter: transcriptional activation by transforming growth factor-beta via SMAD3/beta-catenin cooperation. J Biol Chem 2009;284:31523-31531.  
63. Alexaki VI, Javelaud D, Van Kempen LC, Mohammad KS, Dennler S, Luciani F, et al. GLI2-mediated melanoma invasion and metastasis. J Natl Cancer Inst 2010;102:1148-1159.  
64. Dissanayake SK, Olkhanud PB, O’Connell MP, Carter A, French AD, Camilli TC, et al. Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res 2008;68:10205-10214.
65. Reddy S, Andl T, Bagasra A, Lu MM, Epstein DJ, Morrissey EE, et al. Characterization of Wnt gene expression in developing and postnatal hair follicles and identification of Wnt5a as a target of Sonic hedgehog in hair follicle morphogenesis. Mech Dev 2001;107:69-82.

66. Sterling JA, Oyajobi BO, Grubbs B, Padalecki SS, Munoz SA, Gupta A, et al. The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. Cancer Res 2006;66:7548-7553.

67. Girotti MR, Fernández M, López JA, Camafeita E, Fernández EA, Albar JP, et al. SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I/a 2,b 1 integrin axis. J Invest Dermatol 2011;131:2438-2447.

68. Ungerer C, Doberstein K, Bürger C, Hardt K, Boehncke WH, Böhm B, et al. ADAM15 expression is downregulated in metastatic melanoma compared to primary melanoma. Biochem Biophys Res Commun 2010;401:363-369.

69. Trochon-Joseph V, Martel-Renoir D, Mir LM, Thomaïdis A, Ungerer C, Doberstein K, Bürger C, Hardt K, Boehncke WH, Böhm B, et al. ADAM15 expression is downregulated in metastatic melanoma compared to primary melanoma. Biochem Biophys Res Commun 2010;401:363-369.

70. Yin M, Soikkeli J, Jahkola T, Virolainen S, Saksela O, Hölttä E. TGF-β signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells. Am J Pathol 2012;181:2202-2216.

71. Sun J, He H, Xiong Y, Lu S, Shen J, Cheng A, et al. Fascin protein is critical for transforming growth factor β protein-induced invasion and filopodia formation in spindle-shaped tumor cells. J Biol Chem 2011;286:38865-38875.

72. Nummela P, Lamm J, Soikkeli J, Saksela O, Lahdenpöör H, Hölttä E. Transforming growth factor beta-induced (TGFBI) is an anti-adhesive protein regulating the invasive growth of melanoma cells. Am J Pathol 2012;180:1663-1674.

73. Onichtchouk D, Chen YG, Dosch R, Gavanttka V, Delius H, Massagué J, et al. Silencing of TGF-beta signalling by the pseudoreceptor BAMB1. Nature 1999;401:480-485.

74. Degen WG, Weterman MA, van Groningen JJ, Cornelissen IM, Lemmers JP, Agterbos MA, et al. Expression of nma, a novel gene, inversely correlates with the metastatic potential of human melanoma cell lines and xenografts. Int J Cancer 1996;65:460-465.

75. Berkling C, Takemoto R, Schaider H, Showe L, Satyamoorthy K, Robbins P, et al. Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling. Cancer Res 2001;61:8306-8316.

76. Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 2007;67:10123-10128.

77. Liu G, Zhang F, Lee J, Dong Z. Selective induction of interleukin-8 expression in metastatic melanoma cells by transforming growth factor-beta 1. Cytokine 2005;31:241-249.

78. Orecchia P, Conte R, Balza E, Castellani P, Borsì L, Zardi L, et al. Identification of a novel cell binding site of peristin involved in tumour growth. Eur J Cancer 2011;47:2221-2229.

79. Penauerte C, Bautista-Lopez N, Bouchentouf M, Birman E, Fomer K, Galipeau J. Novel TGF-beta antagonist inhibits tumor growth and angiogenesis by inducing IL-2 receptor-driven STAT1 activation. J Immunol 2011;186:6933-6944.

80. Nesbit M, Schaid H, Miller TH, Herlyn M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol 2001;166:6483-6490.

81. Díaz-Valdés N, Basagotti M, Dotor J, Aranda F, Monreal I, Riezu-Boj JL, et al. Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression. Cancer Res 2011;71:812-821.

82. Oettle H, Seufferlein T, Luger T, Schmid RM, von Wichert G, Endlicher E, et al. Final results of a phase II/I study in patients with pancreatic cancer, malignant melanoma, and colorectal carcinoma with trabedersen. J Clin Oncol 2012;30(Suppl):abstr 4034.

83. Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-β targeted cancer therapy. Int J Biol Sci 2012;8:964-978.

84. Morris JC, Shapiro GI, Tan AR, Lawrence DP, Olenczi TE, Dezube BJ, et al. Phase I/I study of GC1008: A human anti-transforming growth factor-beta (TGF β) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). J Clin Oncol 2008;26(20 Suppl):abstr 9028.

85. Orphanos GS, Ioannidis GN, Ardanavis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 2009;48:964-970.

86. Olivares J, Kumar P, Yu Y, Maples PB, Senzer N, Bedell C, et al. Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin Cancer Res 2011;17:183-192.

87. Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, et al. Phase I trial of "bi-shRNAIturin/(GM)CSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Mol Ther 2012;20:679-686.

88. Park J, Wrzesinski SH, Stern E, Look M, Crioscione J, Ragheb R, et al. Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat Mater 2012;11:895-905.